Shattuck Labs, Inc. (STTK) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Shattuck Labs, Inc. is a biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases. Its lead program is SL-325, a first-in-class death receptor 3 (DR3) antagonist antibody for inflammatory bowel disease (IBD). The company discontinued clinical development of its prior candidate, SL-172154, in October 2024.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $0 | $1.6 million | $0 | $2.7 million |
| Net Loss | $(12.5) million | $(21.6) million | $(26.2) million | $(40.1) million |
| Net Loss Per Share | $(0.24) | $(0.42) | $(0.51) | $(0.79) |
| Operating Expenses | $13.0 million | $24.6 million | $27.4 million | $45.7 million |
| Cash & Equivalents (End of Period) | $50.5 million (as of June 30, 2025) | |||
| Accumulated Deficit | ||||
| Debt | No long-term debt reported; liabilities consist primarily of operating leases and accrued expenses. |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped to zero in Q2 2025 compared to $1.6 million in Q2 2024. This is due to the completion of all obligations under collaboration agreements with Ono Pharmaceutical and ImmunoGen in 2024.
- Expense Reduction: Operating expenses decreased significantly (54.9% for R&D in Q2) primarily due to the discontinuation of the SL-172154 program and workforce reductions implemented in 2024.
- Improved Loss Profile: Net loss narrowed by 42.2% in Q2 2025 compared to the prior year, driven by the reduction in R&D spend.
- Cash Position: Cash and cash equivalents decreased by $6.9 million during the first six months of 2025, primarily due to operating cash outflows, partially offset by the maturity of investments ($15.6 million).
Guidance, Outlook, and Risks
- Private Placement: On August 4, 2025, the company entered into a securities purchase agreement for a private placement expected to raise approximately $46 million in upfront gross proceeds, with potential additional proceeds of ~$57 million if warrants are exercised. Closing is contingent on FDA clearance of the IND for SL-325.
- Liquidity Outlook: Management believes current cash ($50.5 million) is sufficient to fund operations into 2027. Including anticipated private placement proceeds, the company expects to fund operations into 2029.
- Clinical Timeline: Enrollment for the Phase 1 clinical trial of SL-325 is expected to begin in Q3 2025, with full enrollment completion expected in Q2 2026.
- Nasdaq Compliance Risk: On August 8, 2025, the company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00 per share). The company has 180 days (until February 4, 2026) to regain compliance to avoid delisting.
- Regulatory Changes: The "One Big Beautiful Bill Act" enacted in July 2025 includes tax provisions the company is currently assessing for impact.
Investor Verification Checklist
- Private Placement Closing: Verify the successful closing of the August 2025 private placement and the receipt of the ~$46 million in proceeds.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the February 2026 deadline.
- SL-325 IND Clearance: Confirm the FDA clearance of the Investigational New Drug (IND) application, which is a condition for the private placement closing.
- Cash Burn Rate: Track quarterly cash usage to validate the runway projection into 2027 (current cash) and 2029 (with financing).
- Phase 1 Enrollment: Verify the initiation of patient enrollment in the SL-325 Phase 1 trial in Q3 2025 as planned.